Stockscreener 앱 받기
4.405
15.29%
-0.795
시간 외 거래:
4.41
0.005
+0.11%
전일 마감가:
$5.20
열려 있는:
$4.71
하루 거래량:
3.01M
Relative Volume:
2.84
시가총액:
$343.01M
수익:
$14.79M
순이익/손실:
$-102.44M
주가수익비율:
-1.449
EPS:
-3.04
순현금흐름:
$-91.73M
1주 성능:
-25.59%
1개월 성능:
-25.34%
6개월 성능:
+2.20%
1년 성능:
-22.17%
1일 변동 폭
$3.93
$4.80
1주일 범위
$3.93
$5.88
52주 변동 폭
$2.41
$7.37
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
4.405 | 404.92M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-26 | 개시 | Citigroup | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
SLDB: Barclays Lowers Price Target While Maintaining Overweight Rating | SLDB Stock News - GuruFocus
Chardan Capital Maintains Buy Rating and Price Target on SLDB | - GuruFocus
Is Solid Biosciences Inc. stock positioned for long term growth2025 Institutional Moves & Accurate Entry/Exit Alerts - newser.com
Why Solid Biosciences Inc. stock is trending among retail tradersJuly 2025 Movers & Technical Pattern Based Buy Signals - newser.com
Strategies to average down on Solid Biosciences Inc.Market Trend Report & Weekly Market Pulse Alerts - newser.com
Candlestick signals on Solid Biosciences Inc. stock todayWeekly Profit Report & Daily Volume Surge Trade Alerts - newser.com
How to forecast Solid Biosciences Inc. trends using time seriesJuly 2025 Breakouts & Weekly High Potential Stock Alerts - newser.com
Published on: 2025-11-04 02:33:46 - newser.com
Can Solid Biosciences Inc. stock beat analyst upgradesJuly 2025 Technicals & Community Supported Trade Ideas - newser.com
What momentum indicators show for Solid Biosciences Inc. stockWeekly Investment Report & Fast Momentum Entry Tips - newser.com
Solid Biosciences (SLDB) Reports Promising Interim Data on Duche - GuruFocus
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions - The Manila Times
Solid Biosciences Reports Third Quarter 2025 Financial - GlobeNewswire
Does Solid Biosciences Inc. stock trade at a discount to peersDip Buying & Stock Portfolio Risk Management - newser.com
What’s next for Solid Biosciences Inc. stock price2025 Top Gainers & Community Verified Trade Signals - newser.com
Is Solid Biosciences Inc. stock in correction or buying zoneJuly 2025 Opening Moves & Community Verified Watchlist Alerts - newser.com
How to monitor Solid Biosciences Inc. with trend dashboardsTrade Volume Summary & Advanced Technical Analysis Signals - newser.com
Will Solid Biosciences Inc. stock reach all time highs in 2025Oil Prices & Capital Efficient Trading Techniques - newser.com
What insider trading reveals about Solid Biosciences Inc. stockJuly 2025 Rallies & Fast Exit and Entry Strategy Plans - newser.com
Using flow based indicators on Solid Biosciences Inc.2025 Trade Ideas & Low Drawdown Trading Strategies - newser.com
Using Bollinger Bands to evaluate Solid Biosciences Inc.July 2025 Institutional & Fast Gain Stock Trading Tips - newser.com
Predicting Solid Biosciences Inc. trend using moving averagesJuly 2025 Final Week & Proven Capital Preservation Tips - newser.com
Solid Biosciences Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView
How sustainable is Solid Biosciences Inc. stock dividend payoutWeekly Profit Analysis & Reliable Volume Spike Alerts - newser.com
Applying sector rotation models to Solid Biosciences Inc.Portfolio Performance Summary & Weekly Market Pulse Alerts - newser.com
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
솔리드 바이오 주식 (SLDB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kahn Clare | Director |
Mar 11 '25 |
Buy |
5.34 |
1,860 |
9,924 |
2,960 |
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
1.45%
0.86%
자본화:
|
볼륨(24시간):